Nuvectis Pharma Inc (NVCT)
Healthcare
Biotechnology
21.50 $
-5.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Nuvectis Pharma Inc (NVCT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 48.1% of the shares are freely tradable; institutional investors hold 18.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
18.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
42.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
48.1%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
10.1%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
32Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Group Inc | 3.19 | 845,502 | +21.0 | 12/31/2025 |
| BlackRock Inc | 2.88 | 764,441 | -2.3 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.49 | 659,879 | +0.0 | 03/31/2026 |
| Iridian Asset Management LLC | 2.46 | 651,757 | +11.2 | 03/31/2026 |
| Occam Crest Management L.P. | 1.53 | 407,147 | +7.1 | 03/31/2026 |
| Geode Capital Management, LLC | 1.45 | 384,105 | +5.5 | 03/31/2026 |
| Baldwin Brothers Inc | 1.43 | 378,625 | -2.8 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 1.66 | 439,687 | +0.0 | 04/30/2026 |
| iShares Russell 2000 ETF | 1.31 | 347,546 | +0.9 | 05/29/2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 0.79 | 209,887 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.